Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) (FIND-CKD)



Status and phase

Phase 3


Chronic Kidney Disease
Iron Deficiency Anaemia


Drug: FCM (Ferric carboxymaltose) high ferritin target
Drug: Oral Iron (Ferrous sulphate)
Drug: FCM (Ferric carboxymaltose) low ferritin target

Study type


Funder types




Details and patient eligibility


Phase IIIb study to evaluate the long-term efficacy of ferric carboxymaltose (FCM) (using targeted ferritin levels to determine dosing) or oral iron in non-dialysis-dependent chronic kidney disease (NDD-CKD) subjects with iron deficiency anaemia (IDA).

Full description

After an initial screening period of up to 4 weeks, eligible subjects were randomised (1:1:2) to 1 of the following 3 treatment arms for a period of 52 weeks. FCM regimen (maximum single intravenous doses of 1,000 mg of iron) targeting a ferritin level of 400-600 mcg/L. FCM regimen (maximum single intravenous doses of 200 mg of iron) targeting a ferritin level of 100-200 mcg/L. Daily oral iron with 200 mg iron/day (100 mg twice daily)


626 patients




18+ years old


No Healthy Volunteers

Inclusion criteria

  • At least 18 years of age.
  • NDD-CKD subjects with an estimated glomerular filtration rate (eGFR) ≤60 mL/min/1.73 m2 using modification of diet in renal disease 4 (MDRD-4) calculation.
  • NDD-CKD subjects with an eGFR loss ≤12 mL/min/1.73 m2/year and a predicted eGFR of ≥15 mL/min/1.73 m2 in 12 months.
  • Any single Hb between 9 and 11 g/dL within 4 weeks of randomisation. A value taken as part of routine medical care was used.
  • Any single serum ferritin <100 mcg/L or <200 mcg/L with TSAT <20% within 4 weeks of randomisation. Measurements taken as part of routine medical care were used.
  • ESA naïve; no exposure to ESA in last 4 months prior to randomisation.
  • Females of childbearing potential must have had a negative pregnancy test, using any medically acceptable assessment, prior to randomisation.
  • Before any study specific procedure, the appropriate written informed consent must have been obtained.

Exclusion criteria

  • History of acquired iron overload.
  • Known hypersensitivity reaction to any component of ferrous sulphate or FCM. Subjects with hypersensitivity to other forms of iron were permitted to participate.
  • Documented history of discontinuing oral iron products due to significant gastrointestinal (GI) distress.
  • Screening TSAT >40%.
  • Known active infection, C-reactive protein >20 mg/L, clinically significant overt bleeding, active malignancy (i.e., clinical evidence of current malignancy or not in stable remission for at least 5 years since completion of last treatment with exception of basal cell or squamous cell carcinoma of the skin, and cervical intraepithelial neoplasia).
  • History of chronic alcohol abuse (alcohol consumption >40 g/day).
  • Chronic liver disease and/or screening alanine transaminase or aspartate transaminase above 3 times the upper limit of the normal range.
  • Active human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome or active hepatitis B or C virus infection.
  • Anaemia due to reasons other than iron deficiency (e.g., haemoglobinopathy). Subjects with treated Vitamin B12 or folic acid deficiency were permitted.
  • IV iron and/or blood transfusion in previous 30 days prior to screening (or during the screening period).
  • Oral iron therapy at doses >100 mg/day dosing must have been discontinued at least 1 week prior to randomisation. If subject had received this therapy for >3 months (at doses >100 mg/day) then subject was not eligible. Ongoing use of multivitamins containing iron was permitted.
  • Immunosuppressive therapy that may have led to anaemia (e.g., cyclophosphamide, azathioprine, or mycophenolate mofetil). Steroid therapy was permitted.
  • Currently requiring renal dialysis.
  • Anticipated dialysis or transplant during the study.
  • Anticipated need for surgery that may have resulted in significant bleeding (>100 mL).
  • Currently suffering from chronic heart failure New York Heart Association Class IV.
  • Poorly controlled hypertension (>160 mmHg systolic pressure or >100 mmHg diastolic pressure).
  • Acute coronary syndrome or stroke within the 3 months prior to screening.
  • Currently suffering from concomitant, severe psychiatric disorders or other conditions which, in the opinion of the Investigator, would have made participation unacceptable.
  • Subject was not using adequate contraceptive precautions.
  • Subject of childbearing potential was evidently pregnant (e.g., positive human chorionic gonadotropin test) or was breast feeding.
  • Body weight <35 kg.
  • Subject currently was enrolled in or had not yet completed at least 30 days since ending other investigational device or drug studies, or subject was receiving other investigational agent(s).
  • Subject would not be available for follow-up assessment.
  • Subject had any kind of disorder that compromised the ability of the subject to give written informed consent and/or to comply with study procedures.

Trial design

626 participants in 3 patient groups

FCM (high ferritin target)
Experimental group
Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 400 - 600 mcg/L
Drug: FCM (Ferric carboxymaltose) high ferritin target
FCM (low ferritin target)
Experimental group
Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 100 - 200 mcg/L
Drug: FCM (Ferric carboxymaltose) low ferritin target
Oral Iron
Active Comparator group
Ferrous sulphate 100 mg iron twice daily, continuous
Drug: Oral Iron (Ferrous sulphate)

Trial contacts and locations



Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems